Moderator
Becky Hooper, EVERSANA, Burlington, ON, Canada
Speakers
Kim A. Papp; Ronald Vender; Laura Park-Wyllie; Tim Disher, BSc, RN, PhD, Sandpiper Analytics, West Porters Lake, NS, Canada; Nastaran Abbarin; Rachel Teneralli, MS, PhD; Richard Langley; Amanda M Griffin, MSc, EVERSANA, Halifax, NS, Canada
METHODS: We have highlighted key methodologic considerations to outline best practices and aim to encourage clinicians to consider differences in eligibility criteria, baseline risk adjustment, overinterpretation of point estimates, short- and long-term comparisons, and limitations of analyses of safety outcomes when evaluating and interpreting NMAs in psoriasis, to ensure they can be confident in the most up-to-date and robust data to inform their clinical practice.
RESULTS: It is critical that clinicians have the knowledge necessary to assess NMAs accurately. Readers should check that the key assumptions of NMA are satisfied and whether cross trial heterogeneity is present and has been appropriately addressed. Conclusions regarding long-term efficacy should be interpreted with caution as these findings may be interpolated based on short-term results or derived from methods that cannot adequately manage cross-trial heterogeneity.
CONCLUSIONS: Even when NMAs use appropriate methods, conclusions drawn from their results may have a limited context, so it is important for clinicians to be informed by diverse sources of information.
Conference/Value in Health Info
Value in Health, Volume 28, Issue S1
Code
SA3
Topic
Study Approaches
Topic Subcategory
Meta-Analysis & Indirect Comparisons
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Sensory System Disorders (Ear, Eye, Dental, Skin), SDC: Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain), STA: Biologics & Biosimilars